George Reed to Prospective Studies
This is a "connection" page, showing publications George Reed has written about Prospective Studies.
Connection Strength
0.373
-
Reed GW, Collier DH, Koenig AS, Saunders KC, Pappas DA, Litman HJ, Kremer JM, Kotak S. Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis. Arthritis Res Ther. 2017 04 27; 19(1):81.
Score: 0.083
-
Rathbun AM, Harrold LR, Reed GW. A Prospective Evaluation of the Effects of Prevalent Depressive Symptoms on Disease Activity in Rheumatoid Arthritis Patients Treated With Biologic Response Modifiers. Clin Ther. 2016 Jul; 38(7):1759-1772.e3.
Score: 0.079
-
Aripova N, Kremer JM, Pappas DA, Reed G, England BR, Robinson BH, Curtis JR, Thiele GM, Mikuls TR. Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics. Rheumatology (Oxford). 2024 02 01; 63(2):542-550.
Score: 0.033
-
Pappas DA, Nyberg F, Kremer JM, Lampl K, Reed GW, Horne L, Ho M, Onofrei A, Malaviya AN, Rillo OL, Radominski SC, Gal J, Gibofsky A, Popkova TV, Laurindo L, Kerzberg EM, Zahora R, Pons-Estel BA, Curtis JR, Furst DE, Greenberg JD. Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. Clin Rheumatol. 2018 Sep; 37(9):2331-2340.
Score: 0.022
-
Nyberg F, Askling J, Berglind N, Franz?n S, Ho M, Holmqvist M, Horne L, Lampl K, Michaud K, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SM, Wesby-van Swaay E, Yamanaka H, Greenberg JD. Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. Pharmacoepidemiol Drug Saf. 2015 Nov; 24(11):1121-32.
Score: 0.019
-
Harrold LR, Reed GW, Shewade A, Magner R, Saunders KC, John A, Kremer JM, Greenberg JD. Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry. J Rheumatol. 2015 Jul; 42(7):1090-8.
Score: 0.018
-
Gross RL, Schwartzman-Morris JS, Krathen M, Reed G, Chang H, Saunders KC, Fisher MC, Greenberg JD, Putterman C, Mease PJ, Gottlieb AB, Kremer JM, Broder A. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol. 2014 Jun; 66(6):1472-81.
Score: 0.017
-
Pappas DA, Kremer JM, Reed G, Greenberg JD, Curtis JR. "Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients". BMC Musculoskelet Disord. 2014 Apr 01; 15:113.
Score: 0.017
-
Tjia J, Field TS, Mazor KM, Donovan JL, Kanaan AO, Reed G, Doherty P, Harrold LR, Gurwitz JH. Dementia and risk of adverse warfarin-related events in the nursing home setting. Am J Geriatr Pharmacother. 2012 Oct; 10(5):323-30.
Score: 0.015
-
Harrold LR, Harrington JT, Curtis JR, Furst DE, Bentley MJ, Shan Y, Reed G, Kremer J, Greenberg JD. Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. Arthritis Rheum. 2012 Mar; 64(3):630-8.
Score: 0.015
-
Zhang J, Shan Y, Reed G, Kremer J, Greenberg JD, Baumgartner S, Curtis JR. Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. Arthritis Care Res (Hoboken). 2011 Dec; 63(12):1672-9.
Score: 0.014
-
Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, Greenberg JD. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken). 2011 Jun; 63(6):856-64.
Score: 0.014
-
Greenberg JD, Bingham CO, Abramson SB, Reed G, Kishimoto M, Hinkle K, Kremer J. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Arthritis Rheum. 2006 Aug 15; 55(4):543-50.
Score: 0.010
-
Greenberg JD, Bingham CO, Abramson SB, Reed G, Sebaldt RJ, Kremer J. Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. Arthritis Rheum. 2005 Feb 15; 53(1):12-7.
Score: 0.009
-
Schwartz CE, Wheeler HB, Hammes B, Basque N, Edmunds J, Reed G, Ma Y, Li L, Tabloski P, Yanko J. Early intervention in planning end-of-life care with ambulatory geriatric patients: results of a pilot trial. Arch Intern Med. 2002 Jul 22; 162(14):1611-8.
Score: 0.007